Heparin API Market to Reach US$ 2.30 Billion by 2031, Supported by Rising Demand for Anticoagulant Therapies

LOS ANGELES, United States - According to QY Research, the global Heparin API Market is set to experience steady expansion over the coming years, driven by the increasing prevalence of cardiovascular and thrombotic disorders and the growing demand for effective anticoagulant treatments worldwide. As outlined in the newly released report titled "Global Heparin API Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031," the market was valued at US$ 1,23 billion in 2024 and is projected to reach US$ 2,30 billion by 2031, registering a CAGR of 7.8% during the forecast period.

The report delivers a comprehensive, data-driven analysis of the global Heparin API market, combining historical performance with future projections to support informed decision-making and long-term growth strategies. Developed by experienced analysts and subject-matter experts, the study presents validated market data, competitive intelligence, and actionable insights for pharmaceutical manufacturers, suppliers, investors, and healthcare stakeholders.

Get Full PDF Sample Copy of the Report: (Including Full TOC, Tables & Charts): https://qyresearch.in/request-sample/pharma-healthcare-heparin-api-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

What Is the Heparin API Market?
Heparin Active Pharmaceutical Ingredient (API) is a critical anticoagulant used to prevent and treat blood clots in veins, arteries, and lungs, and is widely administered before surgical procedures to reduce thrombotic risk. In commercial production, Heparin API is primarily available in the form of Heparin Sodium API and Heparin Calcium API. This report focuses specifically on Heparin APIs used in pharmaceutical formulations, including applications in unfractionated heparin (UFH) and low molecular weight heparin (LMWH).

Why Is the Heparin API Market Growing?
Market growth is largely fueled by the rising incidence of renal impairment, coronary artery disease, venous thromboembolism, and other cardiovascular conditions. The expansion of global healthcare infrastructure, increasing surgical volumes, and growing awareness of anticoagulant therapies are further strengthening demand for Heparin APIs. In addition, an aging population worldwide continues to increase the burden of chronic conditions requiring long-term anticoagulation, sustaining steady consumption of Heparin-based products.

However, the market also faces notable challenges. Dependence on porcine mucosa as a primary raw material exposes the supply chain to risks such as disease outbreaks, geopolitical disruptions, and raw material price volatility. Regulatory scrutiny related to product quality, safety, and contamination prevention remains high, requiring manufacturers to maintain stringent compliance standards while managing complex production processes and competition from alternative anticoagulants.

How Is the Market Structured and Evolving?
The Heparin API market is segmented by type and application. By type, Heparin Sodium dominates the market, accounting for 96.63% of global revenue in 2024, and is expected to grow from US$ 1,184.01 million in 2024 to US$ 2,228.35 million by 2031. By application, LMWH represents a significant share of demand and is projected to reach US$ 1,977.66 million by 2031, growing at a CAGR of 7.94% during the forecast period.

Competitive Landscape and Key Players -
The report provides a detailed competitive assessment of the global Heparin API market, profiling leading manufacturers based on production capacity, geographic footprint, revenue performance, and strategic initiatives. Major companies operating in the market include Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Pfizer, Nanjing King-friend Biochemical Pharmaceutical, Bioibérica, Changzhou Qianhong Biopharma, Hebei Changshan Biochemical Pharmaceutical, Qingdao Jiulong Biopharmaceutical, Opocrin, Dongying Tiandong Pharmaceutical, Aspen Oss, and others. In 2024, the top five players collectively accounted for approximately 55% of global revenue, highlighting a moderately concentrated competitive environment.

Yantai Dongcheng Pharmaceutical
Shenzhen Hepalink Pharmaceutical
Pfizer
Nanjing King-friend Biochemical Pharmaceutical
Bioibérica
Changzhou Qianhong Biopharma
Hebei Changshan Biochemical Pharmaceutical
Qingdao Jiulong Biopharmaceutical
Opocrin
Dongying Tiandong Pharmaceutical
Aspen Oss
Yino Pharma
Hubei Enoray Biopharmaceutical
Cisen Pharmaceutical

Recent Developments and Industry Trends -
The study tracks recent developments such as mergers and acquisitions, collaborations, product launches, and ongoing research and development activities. These strategic moves illustrate how market leaders are strengthening supply chains, expanding global reach, and enhancing product quality to maintain competitiveness in a tightly regulated pharmaceutical landscape.

Market Segmentation and Regional -

By Type

Heparin Sodium
Heparin Calcium

By Application

UFH
LMWH

The report provides valuable insights into the key segments of the global Heparin API market, with a strong focus on CAGR, market size, market share, and future growth potential. The market is comprehensively segmented by product type, application, and region, with each segment thoroughly analyzed to identify growth prospects, demand patterns, and emerging trends. This detailed segmental analysis plays a crucial role in uncovering high-growth and high-return opportunities across the market. By offering precise data on product- and application-level demand, the report enables businesses to prioritize profitable segments and develop targeted strategies within the global Heparin API market.

Regional Market Outlook -
Regionally, Europe represents the largest consumption market, holding nearly 36.86% of global revenue in 2024, supported by strong pharmaceutical manufacturing and healthcare demand. North America is projected to grow from US$ 431.49 million in 2025 to US$ 671.33 million by 2031, while the Asia-Pacific market is expected to expand at the fastest pace, reaching US$ 799.46 million by 2031 with a CAGR of 8.93%, supported by robust raw material availability and expanding pharmaceutical production in China and other regional markets.

✔ North America (U.S., Canada, China)
✔ Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
✔ Asia-Pacific (Japan, South Korea, China Taiwan, Southeast Asia, India)
✔ Middle East, Africa, Latin America (Brazil, Mexico, Turkey, Israel, GCC Countries)

Reasons to Procure This Report -
The report enables stakeholders to evaluate global, regional, and country-level market trends, assess competitive positioning, identify high-growth segments, and develop targeted investment and expansion strategies. It also supports investors and policymakers by outlining key drivers, risks, and opportunities shaping the future of the Heparin API market.

Key Questions Answered -
What is the current size and future growth outlook of the Heparin API market?

Which product types and applications are driving demand?

What regional markets present the strongest growth opportunities?

How are leading players positioned competitively?

What opportunities and threats influence vendor strategies in the global Heparin API market?

With its in-depth coverage and validated insights, the QY Research report serves as a strategic reference for companies seeking to strengthen their presence and capitalize on emerging opportunities in the global Heparin API market.

Request for Pre-Order / Enquiry Link: https://qyresearch.in/pre-order-inquiry/pharma-healthcare-heparin-api-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031
Table of Contents - Major Key Points:

1 Market Overview
1.1 Heparin API Product Introduction
1.2 Global Heparin API Market Size Forecast
1.2.1 Global Heparin API Sales Value (2020-2031)
1.2.2 Global Heparin API Sales Volume (2020-2031)
1.2.3 Global Heparin API Sales Price (2020-2031)
1.3 Heparin API Market Trends & Drivers
1.3.1 Heparin API Industry Trends
1.3.2 Heparin API Market Drivers & Opportunity
1.3.3 Heparin API Market Challenges
1.3.4 Heparin API Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Heparin API Players Revenue Ranking (2024)
2.2 Global Heparin API Revenue by Company (2020-2025)
2.3 Global Heparin API Players Sales Volume Ranking (2024)
2.4 Global Heparin API Sales Volume by Company Players (2020-2025)
2.5 Global Heparin API Average Price by Company (2020-2025)
2.6 Key Manufacturers Heparin API Manufacturing Base and Headquarters
2.7 Key Manufacturers Heparin API Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Heparin API
2.9 Heparin API Market Competitive Analysis
2.9.1 Heparin API Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Heparin API Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Heparin API as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Heparin Sodium
3.1.2 Heparin Calcium
3.2 Global Heparin API Sales Value by Type
3.2.1 Global Heparin API Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Heparin API Sales Value, by Type (2020-2031)
3.2.3 Global Heparin API Sales Value, by Type (%) (2020-2031)
3.3 Global Heparin API Sales Volume by Type
3.3.1 Global Heparin API Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Heparin API Sales Volume, by Type (2020-2031)
3.3.3 Global Heparin API Sales Volume, by Type (%) (2020-2031)
3.4 Global Heparin API Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 UFH
4.1.2 LMWH
4.2 Global Heparin API Sales Value by Application
4.2.1 Global Heparin API Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Heparin API Sales Value, by Application (2020-2031)
4.2.3 Global Heparin API Sales Value, by Application (%) (2020-2031)
4.3 Global Heparin API Sales Volume by Application
4.3.1 Global Heparin API Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Heparin API Sales Volume, by Application (2020-2031)
4.3.3 Global Heparin API Sales Volume, by Application (%) (2020-2031)
4.4 Global Heparin API Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Heparin API Sales Value by Region
5.1.1 Global Heparin API Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Heparin API Sales Value by Region (2020-2025)
5.1.3 Global Heparin API Sales Value by Region (2026-2031)
5.1.4 Global Heparin API Sales Value by Region (%), (2020-2031)
5.2 Global Heparin API Sales Volume by Region
5.2.1 Global Heparin API Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Heparin API Sales Volume by Region (2020-2025)
5.2.3 Global Heparin API Sales Volume by Region (2026-2031)
5.2.4 Global Heparin API Sales Volume by Region (%), (2020-2031)
5.3 Global Heparin API Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Heparin API Sales Value, 2020-2031
5.4.2 North America Heparin API Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Heparin API Sales Value, 2020-2031
5.5.2 Europe Heparin API Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Heparin API Sales Value, 2020-2031
5.6.2 Asia Pacific Heparin API Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Heparin API Sales Value, 2020-2031
5.7.2 South America Heparin API Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Heparin API Sales Value, 2020-2031
5.8.2 Middle East & Africa Heparin API Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Heparin API Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Heparin API Sales Value and Sales Volume
6.2.1 Key Countries/Regions Heparin API Sales Value, 2020-2031
6.2.2 Key Countries/Regions Heparin API Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Heparin API Sales Value, 2020-2031
6.3.2 United States Heparin API Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Heparin API Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Heparin API Sales Value, 2020-2031
6.4.2 Europe Heparin API Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Heparin API Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Heparin API Sales Value, 2020-2031
6.5.2 China Heparin API Sales Value by Type (%), 2024 VS 2031
6.5.3 China Heparin API Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Heparin API Sales Value, 2020-2031
6.6.2 Japan Heparin API Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Heparin API Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Heparin API Sales Value, 2020-2031
6.7.2 South Korea Heparin API Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Heparin API Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Heparin API Sales Value, 2020-2031
6.8.2 Southeast Asia Heparin API Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Heparin API Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Heparin API Sales Value, 2020-2031
6.9.2 India Heparin API Sales Value by Type (%), 2024 VS 2031
6.9.3 India Heparin API Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Yantai Dongcheng Pharmaceutical
7.1.1 Yantai Dongcheng Pharmaceutical Company Information
7.1.2 Yantai Dongcheng Pharmaceutical Introduction and Business Overview
7.1.3 Yantai Dongcheng Pharmaceutical Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Yantai Dongcheng Pharmaceutical Heparin API Product Offerings
7.1.5 Yantai Dongcheng Pharmaceutical Recent Development
7.2 Shenzhen Hepalink Pharmaceutical
7.2.1 Shenzhen Hepalink Pharmaceutical Company Information
7.2.2 Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
7.2.3 Shenzhen Hepalink Pharmaceutical Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Shenzhen Hepalink Pharmaceutical Heparin API Product Offerings
7.2.5 Shenzhen Hepalink Pharmaceutical Recent Development
7.3 Pfizer
7.3.1 Pfizer Company Information
7.3.2 Pfizer Introduction and Business Overview
7.3.3 Pfizer Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Pfizer Heparin API Product Offerings
7.3.5 Pfizer Recent Development
7.4 Nanjing King-friend Biochemical Pharmaceutical
7.4.1 Nanjing King-friend Biochemical Pharmaceutical Company Information
7.4.2 Nanjing King-friend Biochemical Pharmaceutical Introduction and Business Overview
7.4.3 Nanjing King-friend Biochemical Pharmaceutical Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Nanjing King-friend Biochemical Pharmaceutical Heparin API Product Offerings
7.4.5 Nanjing King-friend Biochemical Pharmaceutical Recent Development
7.5 Bioibérica
7.5.1 Bioibérica Company Information
7.5.2 Bioibérica Introduction and Business Overview
7.5.3 Bioibérica Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Bioibérica Heparin API Product Offerings
7.5.5 Bioibérica Recent Development
7.6 Changzhou Qianhong Biopharma
7.6.1 Changzhou Qianhong Biopharma Company Information
7.6.2 Changzhou Qianhong Biopharma Introduction and Business Overview
7.6.3 Changzhou Qianhong Biopharma Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Changzhou Qianhong Biopharma Heparin API Product Offerings
7.6.5 Changzhou Qianhong Biopharma Recent Development
7.7 Hebei Changshan Biochemical Pharmaceutical
7.7.1 Hebei Changshan Biochemical Pharmaceutical Company Information
7.7.2 Hebei Changshan Biochemical Pharmaceutical Introduction and Business Overview
7.7.3 Hebei Changshan Biochemical Pharmaceutical Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Hebei Changshan Biochemical Pharmaceutical Heparin API Product Offerings
7.7.5 Hebei Changshan Biochemical Pharmaceutical Recent Development
7.8 Qingdao Jiulong Biopharmaceutical
7.8.1 Qingdao Jiulong Biopharmaceutical Company Information
7.8.2 Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
7.8.3 Qingdao Jiulong Biopharmaceutical Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Qingdao Jiulong Biopharmaceutical Heparin API Product Offerings
7.8.5 Qingdao Jiulong Biopharmaceutical Recent Development
7.9 Opocrin
7.9.1 Opocrin Company Information
7.9.2 Opocrin Introduction and Business Overview
7.9.3 Opocrin Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Opocrin Heparin API Product Offerings
7.9.5 Opocrin Recent Development
7.10 Dongying Tiandong Pharmaceutical
7.10.1 Dongying Tiandong Pharmaceutical Company Information
7.10.2 Dongying Tiandong Pharmaceutical Introduction and Business Overview
7.10.3 Dongying Tiandong Pharmaceutical Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Dongying Tiandong Pharmaceutical Heparin API Product Offerings
7.10.5 Dongying Tiandong Pharmaceutical Recent Development
7.11 Aspen Oss
7.11.1 Aspen Oss Company Information
7.11.2 Aspen Oss Introduction and Business Overview
7.11.3 Aspen Oss Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Aspen Oss Heparin API Product Offerings
7.11.5 Aspen Oss Recent Development
7.12 Yino Pharma
7.12.1 Yino Pharma Company Information
7.12.2 Yino Pharma Introduction and Business Overview
7.12.3 Yino Pharma Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Yino Pharma Heparin API Product Offerings
7.12.5 Yino Pharma Recent Development
7.13 Hubei Enoray Biopharmaceutical
7.13.1 Hubei Enoray Biopharmaceutical Company Information
7.13.2 Hubei Enoray Biopharmaceutical Introduction and Business Overview
7.13.3 Hubei Enoray Biopharmaceutical Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Hubei Enoray Biopharmaceutical Heparin API Product Offerings
7.13.5 Hubei Enoray Biopharmaceutical Recent Development
7.14 Cisen Pharmaceutical
7.14.1 Cisen Pharmaceutical Company Information
7.14.2 Cisen Pharmaceutical Introduction and Business Overview
7.14.3 Cisen Pharmaceutical Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Cisen Pharmaceutical Heparin API Product Offerings
7.14.5 Cisen Pharmaceutical Recent Development
8 Industry Chain Analysis
8.1 Heparin API Industrial Chain
8.2 Heparin API Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Heparin API Sales Model
8.5.2 Sales Channel
8.5.3 Heparin API Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About Us:

QYResearch established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Contact Us:

Arshad Shaha | Marketing Executive

QY Research, INC.
315 Work Avenue, Raheja Woods,
Survey No. 222/1, Plot No. 25, 6th Floor,
Kayani Nagar, Yervada, Pune 411006, Maharashtra
Tel: +91-8669986909
Emails - arshad@qyrindia.com
Web - https://www.qyresearch.in

This release was published on openPR.